Wei Xu , Jianhui Li

1 Traditional Chinese Medicine Research Center, Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
2 Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 3   
Received: 23 Apr., 2024    Accepted: 28 May, 2024    Published: 07 Jun., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peptide-based vaccines have emerged as a promising approach for the treatment of oral cancer, leveraging the ability to elicit robust anti-tumor immune responses. These vaccines primarily target tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs) to stimulate CD8+cytotoxic T cells and CD4+helper T cells, thereby enhancing the body's immune response against cancer cells. Despite their potential, the clinical efficacy of peptide-based vaccines has been limited due to factors such as insufficient immune cell infiltration and the immunosuppressive tumor microenvironment. Recent advancements have focused on optimizing peptide sequences, incorporating potent adjuvants, and employing combinatorial therapies with immune checkpoint inhibitors to improve clinical outcomes. Personalized peptide vaccines, designed based on individual tumor neoantigens, represent a significant advancement, offering tailored immunotherapy with enhanced specificity and efficacy. This study discusses the mechanisms of action, clinical outcomes, and future prospects of peptide-based vaccines in the context of oral cancer, highlighting the importance of continued research and development to overcome current challenges and improve therapeutic efficacy.

Peptide-based vaccines; Oral cancer; Tumor-associated antigens (TAAs); Immune checkpoint inhibitors; Neoantigen-based vaccines